Business

Recursion Announces Sanofi Options Potential First-in-Class Immunology Development Candidate from Their Collaboration

Financial Post · October 15, 2026 at 9:00 a.m.

Potential first-in-class dual targeting inhibitor oral small molecule to enter Sanofi’s development pipeline, with phase 1 clinical study currently planned to begin in 2027 Salt Lake City, UT, Oct.

15, 2026 (GLOBE NEWSWI

Read the full article on Financial Post ›

5News aggregated this summary from the outlet’s public feed. The full article, with all the context, is on financialpost.com — the content belongs to Financial Post.

Recursion Announces Sanofi Options Potential First-in-Class Immunology Development Candidate from Their Collaboration

More from Financial Post

Paladin Announces Availability of Notice of Meeting for Annual General Meeting

Prime Drink Group Announces Subscription Receipt Financing and Closing of Second Tranche of Private Placement of Units

Solera | Hollander Showcases the Next Era of Automotive Recycling at ARA 2026

Purecore Upsizes Non-Brokered Private Placement to $3.5M

More in Business

Paladin Announces Availability of Notice of Meeting for Annual General Meeting

Prime Drink Group Announces Subscription Receipt Financing and Closing of Second Tranche of Private Placement of Units

Solera | Hollander Showcases the Next Era of Automotive Recycling at ARA 2026

Purecore Upsizes Non-Brokered Private Placement to $3.5M

David Pearson Appointed President of Anthem Properties Group

AGI Third Quarter 2026 Results Release Date and Conference Call